COVID-19危重患者早期蛋白进展的影响:一项多中心基数匹配研究

IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics
Therapeutics and Clinical Risk Management Pub Date : 2025-02-21 eCollection Date: 2025-01-01 DOI:10.2147/TCRM.S487662
Abdulrahman Alissa, Ghazwa B Korayem, Ohoud Aljuhani, Mashael AlFaifi, Lina I Alnajjar, Noura A L Souaan, Meshal Albassam, Aljoharah Alrayes, Sara Albishi, Reem Abdullah Alqahtani, Abdullah F Alharthi, Nasser Alkhushaym, Mohammed A Alhammad, Ramesh Vishwakarma, Aisha Alharbi, Samiah Alsohimi, Abdalmohsen Ababtain, Hasan M Al-Dorzi, Rahaf Alqahtani, Ghadah Almuaither, Layan A Alarifi, Ahlam Almutairi, Mada B Alharbi, Abeer A Alghamdi, Munirah F Alhmoud, Khalid Al Sulaiman
{"title":"COVID-19危重患者早期蛋白进展的影响:一项多中心基数匹配研究","authors":"Abdulrahman Alissa, Ghazwa B Korayem, Ohoud Aljuhani, Mashael AlFaifi, Lina I Alnajjar, Noura A L Souaan, Meshal Albassam, Aljoharah Alrayes, Sara Albishi, Reem Abdullah Alqahtani, Abdullah F Alharthi, Nasser Alkhushaym, Mohammed A Alhammad, Ramesh Vishwakarma, Aisha Alharbi, Samiah Alsohimi, Abdalmohsen Ababtain, Hasan M Al-Dorzi, Rahaf Alqahtani, Ghadah Almuaither, Layan A Alarifi, Ahlam Almutairi, Mada B Alharbi, Abeer A Alghamdi, Munirah F Alhmoud, Khalid Al Sulaiman","doi":"10.2147/TCRM.S487662","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Limited evidence is available regarding the safety and effectiveness of early high protein intake in critically ill patients with COVID-19. Therefore, this study aims to assess the safety of early protein advancement during nutritional support in these patients.</p><p><strong>Methods: </strong>A multi-center retrospective cohort study included adult critically ill patients with COVID-19 admitted to Intensive Care Units (ICUs) at three centers in Saudi Arabia. Patients were grouped into two groups based on the protein intake at day three of feeding initiation into low protein (≤0.8 mg/kg/day) versus high protein (>0.8 mg/kg/day) groups. Acute kidney injury (AKI) during the ICU stay was the primary endpoint, while the remaining were considered secondary endpoints.</p><p><strong>Results: </strong>The study included 466 patients, but after cardinality matching with a 2:1 ratio, 192 were in the lower protein group compared with 96 patients in the high protein group. The rate of AKI was low in the highprotein group compared with the low protein group on day three of feeding initiation (19.9% versus 12.7%); however, this was not statistically significant (OR 0.54; 95% CI 0.26, 1.33; p=0.2). Additionally, patients in the high protein group had a higher rate of atrial fibrillation than those in the low protein group (OR 2.33; 95% CI 1.18, 4.62; p=0.02). No differences were observed in 30-day and in-hospital mortality (HR1.33, 95% CI 0.91, 1.96; p=0.14 and HR 1.21, 95% CI: 0.85, 1.72; p=0.29, respectively).</p><p><strong>Conclusion: </strong>The advancement of protein in critically ill patients with COVID-19 was not associated with significant differences in the incidence of AKI. In contrast, the early advancement of protein in nutritional feeding within the first three days was associated with a higher incidence of atrial fibrillation.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"177-189"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853109/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Impact of Early Protein Advancement in Critically Ill Patients with COVID-19: A Multicenter Cardinality Matching Study.\",\"authors\":\"Abdulrahman Alissa, Ghazwa B Korayem, Ohoud Aljuhani, Mashael AlFaifi, Lina I Alnajjar, Noura A L Souaan, Meshal Albassam, Aljoharah Alrayes, Sara Albishi, Reem Abdullah Alqahtani, Abdullah F Alharthi, Nasser Alkhushaym, Mohammed A Alhammad, Ramesh Vishwakarma, Aisha Alharbi, Samiah Alsohimi, Abdalmohsen Ababtain, Hasan M Al-Dorzi, Rahaf Alqahtani, Ghadah Almuaither, Layan A Alarifi, Ahlam Almutairi, Mada B Alharbi, Abeer A Alghamdi, Munirah F Alhmoud, Khalid Al Sulaiman\",\"doi\":\"10.2147/TCRM.S487662\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Limited evidence is available regarding the safety and effectiveness of early high protein intake in critically ill patients with COVID-19. Therefore, this study aims to assess the safety of early protein advancement during nutritional support in these patients.</p><p><strong>Methods: </strong>A multi-center retrospective cohort study included adult critically ill patients with COVID-19 admitted to Intensive Care Units (ICUs) at three centers in Saudi Arabia. Patients were grouped into two groups based on the protein intake at day three of feeding initiation into low protein (≤0.8 mg/kg/day) versus high protein (>0.8 mg/kg/day) groups. Acute kidney injury (AKI) during the ICU stay was the primary endpoint, while the remaining were considered secondary endpoints.</p><p><strong>Results: </strong>The study included 466 patients, but after cardinality matching with a 2:1 ratio, 192 were in the lower protein group compared with 96 patients in the high protein group. The rate of AKI was low in the highprotein group compared with the low protein group on day three of feeding initiation (19.9% versus 12.7%); however, this was not statistically significant (OR 0.54; 95% CI 0.26, 1.33; p=0.2). Additionally, patients in the high protein group had a higher rate of atrial fibrillation than those in the low protein group (OR 2.33; 95% CI 1.18, 4.62; p=0.02). No differences were observed in 30-day and in-hospital mortality (HR1.33, 95% CI 0.91, 1.96; p=0.14 and HR 1.21, 95% CI: 0.85, 1.72; p=0.29, respectively).</p><p><strong>Conclusion: </strong>The advancement of protein in critically ill patients with COVID-19 was not associated with significant differences in the incidence of AKI. In contrast, the early advancement of protein in nutritional feeding within the first three days was associated with a higher incidence of atrial fibrillation.</p>\",\"PeriodicalId\":22977,\"journal\":{\"name\":\"Therapeutics and Clinical Risk Management\",\"volume\":\"21 \",\"pages\":\"177-189\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-02-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853109/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutics and Clinical Risk Management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/TCRM.S487662\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S487662","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

背景:关于COVID-19危重患者早期高蛋白摄入的安全性和有效性的证据有限。因此,本研究旨在评估这些患者在营养支持期间早期蛋白质进展的安全性。方法:一项多中心回顾性队列研究纳入了沙特阿拉伯三个中心重症监护病房(icu)的成年COVID-19危重患者。根据开始喂养第3天的蛋白质摄入量将患者分为低蛋白组(≤0.8 mg/kg/天)和高蛋白组(>0.8 mg/kg/天)。ICU住院期间的急性肾损伤(AKI)是主要终点,而其余被认为是次要终点。结果:本研究纳入466例患者,但经2:1比例基数匹配后,低蛋白组192例,高蛋白组96例。饲喂第3天,高蛋白组AKI发生率低于低蛋白组(19.9% vs 12.7%);然而,这没有统计学意义(OR 0.54;95% ci 0.26, 1.33;p = 0.2)。此外,高蛋白组患者的房颤发生率高于低蛋白组(OR 2.33;95% ci 1.18, 4.62;p = 0.02)。30天死亡率和住院死亡率无差异(HR1.33, 95% CI 0.91, 1.96;p=0.14, HR 1.21, 95% CI: 0.85, 1.72;分别为p = 0.29)。结论:COVID-19危重患者蛋白进展与AKI发生率无显著差异。相反,在前三天营养喂养中蛋白质的早期进展与房颤的高发生率相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Impact of Early Protein Advancement in Critically Ill Patients with COVID-19: A Multicenter Cardinality Matching Study.

Background: Limited evidence is available regarding the safety and effectiveness of early high protein intake in critically ill patients with COVID-19. Therefore, this study aims to assess the safety of early protein advancement during nutritional support in these patients.

Methods: A multi-center retrospective cohort study included adult critically ill patients with COVID-19 admitted to Intensive Care Units (ICUs) at three centers in Saudi Arabia. Patients were grouped into two groups based on the protein intake at day three of feeding initiation into low protein (≤0.8 mg/kg/day) versus high protein (>0.8 mg/kg/day) groups. Acute kidney injury (AKI) during the ICU stay was the primary endpoint, while the remaining were considered secondary endpoints.

Results: The study included 466 patients, but after cardinality matching with a 2:1 ratio, 192 were in the lower protein group compared with 96 patients in the high protein group. The rate of AKI was low in the highprotein group compared with the low protein group on day three of feeding initiation (19.9% versus 12.7%); however, this was not statistically significant (OR 0.54; 95% CI 0.26, 1.33; p=0.2). Additionally, patients in the high protein group had a higher rate of atrial fibrillation than those in the low protein group (OR 2.33; 95% CI 1.18, 4.62; p=0.02). No differences were observed in 30-day and in-hospital mortality (HR1.33, 95% CI 0.91, 1.96; p=0.14 and HR 1.21, 95% CI: 0.85, 1.72; p=0.29, respectively).

Conclusion: The advancement of protein in critically ill patients with COVID-19 was not associated with significant differences in the incidence of AKI. In contrast, the early advancement of protein in nutritional feeding within the first three days was associated with a higher incidence of atrial fibrillation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-
CiteScore
5.30
自引率
3.60%
发文量
139
审稿时长
16 weeks
期刊介绍: Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信